A new regulatory milestone: what the joint FDA and EMA’s AI principles can mean for clinical trial technology
Author: Elizabeth Lavin, Chief Quality Officer, Suvoda
Posts by Suvoda:
IRT vs. RTSM: what’s the difference? What sponsors need to know when choosing clinical trial technology
Author: Heather Nonnemacher, Director of Services Solutions, Suvoda
Technology fragmentation is one of the biggest hidden risks in clinical trials
By Kathy Kohler, Vice President, Customer Success at Suvoda
What patients are asking for in clinical trials, according to the CISCRP 2025 survey
Editor: Dave Hine, Senior Director, Solutions Consulting at Suvoda
RTSM (IRT) FAQ: A guide to Randomization and Trial Supply Management technology for clinical trials
What you need to know about RTSM software systems, also known as Interactive Response Technology...
Clinical trial technology 2026 outlook: five big ideas from Suvoda leaders
Author: Elena Filimonova, Chief Marketing Officer
A conversation with E.K. Koh, Chief Product Officer: how Suvoda is shaping the future of clinical trial technology
Author: Elena Filimonova, Chief Marketing Officer
Less friction, more focus: Rethinking technology for patients and sites in clinical trials
Author: Heather Nonnemacher, Director of Services Solutions, Suvoda
What the Suvoda-Greenphire merger means for clinical trials
Author: Steve Geffon, Chief Commercial Officer
Snapshot:
- Suvoda and Greenphire merger changes the...
Solving problems and building partnerships: a conversation with Suvoda Chief Commercial Officer, Steve Geffon
Author: Elena Filimonova, Chief Marketing Officer
Snapshot:
- Commercial teams solve problems:...